Cardiometabolic Risk of Obese Subjects: Cross-sectional Study

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Nov 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the health risks related to obesity, particularly how it affects the heart and metabolism. The researchers want to understand these risks from various angles, including genetics (the study of genes), clinical assessments (medical exams), and laboratory tests (experiments in a lab). They are currently looking for participants aged 18 and older who have a body mass index (BMI) greater than 30, which means they are considered obese. Participants should not have certain medical conditions, such as severe diabetes or specific types of high cholesterol, and they must be able to communicate and follow the study's guidelines.

If you or someone you know is eligible and decides to join, you can expect to contribute to important research that may help improve the understanding of obesity and its related health risks. Participants will have the chance to undergo various assessments and tests that can provide valuable information about their health. Joining this study requires a willingness to participate and give consent, and it takes place in a supportive environment focused on understanding and managing obesity-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Age \> 18 years
• • BMI \> 30 Kg/m2
• • In primary prevention for cardiovascular disease
• • Ability to communicate, make themselves understood and adhere to study-specific procedures
• • Willingness to participate in the study and obtain informed consent
• Exclusion Criteria:
• • Patients already enrolled by the Research Units involved in the enrolment
• • Glycated hemoglobin level \> 55 mmol/L
• • Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes
• • Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS\>8)
• • Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies
• • Patients suffering from systemic inflammatory or oncological diseases
• • Patients on active treatment with GLP-1 analogues
• • Pregnancy and breastfeeding
• • Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.